It is also too early to know what impact quitting has on long-term health (Youmshajekian) Acknowledgements This piece was originally published in April 2025 by Lara Marks with the generous help of Svetlana Mojsov, Jens Holst and Richard Ng who read early drafts
This is not a single-target drug
A low level of carnitine in the blood indicates a deficiency
Single-mechanism research addresses one pathway at a time
TB-500, a synthesized fragment, mirrors many of TB4's systemic repair properties and is known to distribute broadly throughout the body, supporting healing across multiple tissue types simultaneously
In this study, the effect size identified for reduction in stroke risk (HR 0.74) is comparable to or exceeds that of meta-analyses investigating the effects of lowering blood pressure (RR 0.73), treating hyperlipidemia (RR 0.79), and other interventions in people with T2D [30], highlighting the benefits that can be achieved by adding GLP-1 RAs to antihyperglycemic regimens
